Theodore R Levin1, Christopher D Jensen2, Neetu M Chawla3, Lori C Sakoda4, Jeffrey K Lee4, Wei K Zhao4, Molly A Landau5, Ariel Herm6, Eryn Eby5, Charles P Quesenberry4, Douglas A Corley4. 1. Kaiser Permanente Medical Center, Walnut Creek, California; Division of Research, Kaiser Permanente Northern California, Oakland, California. 2. Division of Research, Kaiser Permanente Northern California, Oakland, California. Electronic address: christopher.d.jensen@kp.org. 3. Division of Research, Kaiser Permanente Northern California, Oakland, California; Veterans Administration, Los Angeles, California. 4. Division of Research, Kaiser Permanente Northern California, Oakland, California. 5. The Permanente Medical Group Consulting Services, Kaiser Permanente Northern California, California. 6. Regional Health Education, Kaiser Permanente Northern California, California.
Abstract
BACKGROUND & AIMS: Some guidelines recommend starting colorectal cancer (CRC) screening before age 50 years for African Americans, but there are few data on screening uptake and yield in this population. METHODS: We performed a prospective study of fecal immunochemical test (FIT) screening among African American members of the Kaiser Permanente Northern California health plan. We compared data from African American members screened when they were 45-50 years old (early screening group) in 2018 with data from previously unscreened African American, white, Hispanic, and Asian/Pacific Islander health plan members who were 51-56 years old. Screening outreach was performed with mailed FIT kits. Logistic regression models, adjusted for sex, were used to evaluate differences among groups in screening uptake, colonoscopy follow-up of abnormal test results, and test yield. RESULTS: Among 10,232 African Americans in the early screening group who were mailed a FIT, screening was completed by 33.1%. Among the 4% with positive test results, 85.3% completed a follow-up colonoscopy: 57.8% had any adenoma, 33.6% had an advanced adenoma (adenoma with advanced histology or polyp ≥10 mm), and 2.6% were diagnosed with CRC. African Americans in the early screening group were modestly more likely to have completed screening than previously unscreened African Americans, whites, and Hispanics 51-56 years old. The groups did not differ significantly in positive results from the FIT (range, 3.8%-4.6%) and more than 74% received a follow-up colonoscopy after a positive test result. The test yields for any adenoma (range, 56.7%-70.7%), advanced adenoma (range, 20.0%-33.6%), and CRC (range, 0%-7.1%) were similar. CONCLUSIONS: Proportions of African Americans who participated in early (aged 45-50 years) FIT screening and test yield were comparable to those of previously unscreened African Americans, whites, Hispanics, and Asian/Pacific Islanders who were 51-56 years old.
BACKGROUND & AIMS: Some guidelines recommend starting colorectal cancer (CRC) screening before age 50 years for African Americans, but there are few data on screening uptake and yield in this population. METHODS: We performed a prospective study of fecal immunochemical test (FIT) screening among African American members of the Kaiser Permanente Northern California health plan. We compared data from African American members screened when they were 45-50 years old (early screening group) in 2018 with data from previously unscreened African American, white, Hispanic, and Asian/Pacific Islander health plan members who were 51-56 years old. Screening outreach was performed with mailed FIT kits. Logistic regression models, adjusted for sex, were used to evaluate differences among groups in screening uptake, colonoscopy follow-up of abnormal test results, and test yield. RESULTS: Among 10,232 African Americans in the early screening group who were mailed a FIT, screening was completed by 33.1%. Among the 4% with positive test results, 85.3% completed a follow-up colonoscopy: 57.8% had any adenoma, 33.6% had an advanced adenoma (adenoma with advanced histology or polyp ≥10 mm), and 2.6% were diagnosed with CRC. African Americans in the early screening group were modestly more likely to have completed screening than previously unscreened African Americans, whites, and Hispanics 51-56 years old. The groups did not differ significantly in positive results from the FIT (range, 3.8%-4.6%) and more than 74% received a follow-up colonoscopy after a positive test result. The test yields for any adenoma (range, 56.7%-70.7%), advanced adenoma (range, 20.0%-33.6%), and CRC (range, 0%-7.1%) were similar. CONCLUSIONS: Proportions of African Americans who participated in early (aged 45-50 years) FIT screening and test yield were comparable to those of previously unscreened African Americans, whites, Hispanics, and Asian/Pacific Islanders who were 51-56 years old.
Authors: Rachel B Issaka; Maneesh H Singh; Sachiko M Oshima; Victoria J Laleau; Carly D Rachocki; Ellen H Chen; Lukejohn W Day; Urmimala Sarkar; Ma Somsouk Journal: Am J Gastroenterol Date: 2016-12-13 Impact factor: 10.864
Authors: Andrew M D Wolf; Elizabeth T H Fontham; Timothy R Church; Christopher R Flowers; Carmen E Guerra; Samuel J LaMonte; Ruth Etzioni; Matthew T McKenna; Kevin C Oeffinger; Ya-Chen Tina Shih; Louise C Walter; Kimberly S Andrews; Otis W Brawley; Durado Brooks; Stacey A Fedewa; Deana Manassaram-Baptiste; Rebecca L Siegel; Richard C Wender; Robert A Smith Journal: CA Cancer J Clin Date: 2018-05-30 Impact factor: 508.702
Authors: Shivan J Mehta; Christopher D Jensen; Virginia P Quinn; Joanne E Schottinger; Ann G Zauber; Reinier Meester; Adeyinka O Laiyemo; Stacey Fedewa; Michael Goodman; Robert H Fletcher; Theodore R Levin; Douglas A Corley; Chyke A Doubeni Journal: J Gen Intern Med Date: 2016-07-13 Impact factor: 5.128
Authors: Hermann Brenner; Jenny Chang-Claude; Christoph M Seiler; Alexander Rickert; Michael Hoffmeister Journal: Ann Intern Med Date: 2011-01-04 Impact factor: 25.391
Authors: Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Jolanda de Boer; Theodore R Levin; Chyke Doubeni; Bruce H Fireman; Charles P Quesenberry Journal: Clin Gastroenterol Hepatol Date: 2012-09-14 Impact factor: 11.382
Authors: Christopher D Jensen; Douglas A Corley; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Wei K Zhao; Amy R Marks; Joanne E Schottinger; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Carrie N Klabunde; Charles P Quesenberry; Theodore R Levin; Pauline A Mysliwiec Journal: Ann Intern Med Date: 2016-01-26 Impact factor: 25.391
Authors: Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Jeffrey K Lee; Chyke A Doubeni; Ann G Zauber; Jolanda de Boer; Bruce H Fireman; Joanne E Schottinger; Virginia P Quinn; Nirupa R Ghai; Theodore R Levin; Charles P Quesenberry Journal: N Engl J Med Date: 2014-04-03 Impact factor: 91.245
Authors: Douglas A Corley; Christopher D Jensen; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Joanne E Schottinger; Amy R Marks; Wei K Zhao; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Charles P Quesenberry; Bruce H Fireman; Theodore R Levin Journal: JAMA Date: 2017-04-25 Impact factor: 56.272
Authors: John S Luque; Matthew Vargas; Kristin Wallace; Olayemi O Matthew; Rima Tawk; Askal A Ali; Gebre-Egziabher Kiros; Cynthia M Harris; Clement K Gwede Journal: J Cancer Educ Date: 2021-04-26 Impact factor: 1.771